CN1495272A - 选择标记物的方法 - Google Patents
选择标记物的方法 Download PDFInfo
- Publication number
- CN1495272A CN1495272A CNA031312047A CN03131204A CN1495272A CN 1495272 A CN1495272 A CN 1495272A CN A031312047 A CNA031312047 A CN A031312047A CN 03131204 A CN03131204 A CN 03131204A CN 1495272 A CN1495272 A CN 1495272A
- Authority
- CN
- China
- Prior art keywords
- gene
- framework
- expression
- seq
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 60
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 111
- 230000014509 gene expression Effects 0.000 claims abstract description 76
- 239000003550 marker Substances 0.000 claims description 37
- 238000005457 optimization Methods 0.000 claims description 13
- 238000003745 diagnosis Methods 0.000 claims description 7
- 230000008676 import Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 abstract description 7
- 108700026220 vif Genes Proteins 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 99
- 239000000523 sample Substances 0.000 description 46
- 230000002068 genetic effect Effects 0.000 description 17
- 238000004393 prognosis Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000002493 microarray Methods 0.000 description 14
- 238000001514 detection method Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 108020004635 Complementary DNA Proteins 0.000 description 6
- 238000010804 cDNA synthesis Methods 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 206010009944 Colon cancer Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 108700032475 Sex-Determining Region Y Proteins 0.000 description 4
- 102100022978 Sex-determining region Y protein Human genes 0.000 description 4
- 201000010989 colorectal carcinoma Diseases 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102100039339 Atrial natriuretic peptide receptor 1 Human genes 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 101000961044 Homo sapiens Atrial natriuretic peptide receptor 1 Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002969 morbid Effects 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102100024005 Acid ceramidase Human genes 0.000 description 2
- 102100026663 All-trans-retinol dehydrogenase [NAD(+)] ADH7 Human genes 0.000 description 2
- 102100024152 Cadherin-17 Human genes 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 2
- 108020004394 Complementary RNA Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100033423 GDNF family receptor alpha-1 Human genes 0.000 description 2
- 101000975753 Homo sapiens Acid ceramidase Proteins 0.000 description 2
- 101000690766 Homo sapiens All-trans-retinol dehydrogenase [NAD(+)] ADH7 Proteins 0.000 description 2
- 101000762247 Homo sapiens Cadherin-17 Proteins 0.000 description 2
- 101000888572 Homo sapiens Calcium-activated chloride channel regulator 1 Proteins 0.000 description 2
- 101000997961 Homo sapiens GDNF family receptor alpha-1 Proteins 0.000 description 2
- 101001091385 Homo sapiens Kallikrein-6 Proteins 0.000 description 2
- 101000958771 Homo sapiens N-acylethanolamine-hydrolyzing acid amidase Proteins 0.000 description 2
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 2
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102100034866 Kallikrein-6 Human genes 0.000 description 2
- 102000047724 Member 2 Solute Carrier Family 12 Human genes 0.000 description 2
- 101000690769 Mus musculus All-trans-retinol dehydrogenase [NAD(+)] ADH7 Proteins 0.000 description 2
- 102100038360 N-acylethanolamine-hydrolyzing acid amidase Human genes 0.000 description 2
- 101150060710 NPR1 gene Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 102100038358 Prostate-specific antigen Human genes 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 108091006620 SLC12A2 Proteins 0.000 description 2
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 2
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 2
- 102100027881 Tumor protein 63 Human genes 0.000 description 2
- 101710140697 Tumor protein 63 Proteins 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 210000003040 circulating cell Anatomy 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000003184 complementary RNA Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 238000001558 permutation test Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150094765 70 gene Proteins 0.000 description 1
- 102100028186 ATP-binding cassette sub-family C member 5 Human genes 0.000 description 1
- 102100026437 Branched-chain-amino-acid aminotransferase, cytosolic Human genes 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010083123 CDX2 Transcription Factor Proteins 0.000 description 1
- 102000006277 CDX2 Transcription Factor Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 241000255749 Coccinellidae Species 0.000 description 1
- 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
- 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
- 102100023419 Cystic fibrosis transmembrane conductance regulator Human genes 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 101710166358 Globin-1 Proteins 0.000 description 1
- 102100036241 HLA class II histocompatibility antigen, DQ beta 1 chain Human genes 0.000 description 1
- 108010065026 HLA-DQB1 antigen Proteins 0.000 description 1
- 108010020382 Hepatocyte Nuclear Factor 1-alpha Proteins 0.000 description 1
- 108010061414 Hepatocyte Nuclear Factor 1-beta Proteins 0.000 description 1
- 102100022057 Hepatocyte nuclear factor 1-alpha Human genes 0.000 description 1
- 102100022123 Hepatocyte nuclear factor 1-beta Human genes 0.000 description 1
- 102100038009 High affinity immunoglobulin epsilon receptor subunit beta Human genes 0.000 description 1
- 102100031672 Homeobox protein CDX-1 Human genes 0.000 description 1
- 102100030231 Homeobox protein cut-like 2 Human genes 0.000 description 1
- 108010048671 Homeodomain Proteins Proteins 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 101000986622 Homo sapiens ATP-binding cassette sub-family C member 5 Proteins 0.000 description 1
- 101000766268 Homo sapiens Branched-chain-amino-acid aminotransferase, cytosolic Proteins 0.000 description 1
- 101000907783 Homo sapiens Cystic fibrosis transmembrane conductance regulator Proteins 0.000 description 1
- 101000878594 Homo sapiens High affinity immunoglobulin epsilon receptor subunit beta Proteins 0.000 description 1
- 101000777808 Homo sapiens Homeobox protein CDX-1 Proteins 0.000 description 1
- 101000726714 Homo sapiens Homeobox protein cut-like 2 Proteins 0.000 description 1
- 101000977762 Homo sapiens Iroquois-class homeodomain protein IRX-5 Proteins 0.000 description 1
- 101000605528 Homo sapiens Kallikrein-2 Proteins 0.000 description 1
- 101001056452 Homo sapiens Keratin, type II cytoskeletal 6A Proteins 0.000 description 1
- 101000984192 Homo sapiens Leukocyte immunoglobulin-like receptor subfamily B member 3 Proteins 0.000 description 1
- 101000739159 Homo sapiens Mammaglobin-A Proteins 0.000 description 1
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 1
- 101001133081 Homo sapiens Mucin-2 Proteins 0.000 description 1
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 1
- 101001057168 Homo sapiens Protein EVI2B Proteins 0.000 description 1
- 101100140242 Homo sapiens RDH11 gene Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000873502 Homo sapiens S-adenosylmethionine decarboxylase proenzyme Proteins 0.000 description 1
- 101000642262 Homo sapiens Spondin-1 Proteins 0.000 description 1
- 101000946167 Homo sapiens Transcription factor LBX1 Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010061833 Integrases Proteins 0.000 description 1
- 102100023529 Iroquois-class homeodomain protein IRX-5 Human genes 0.000 description 1
- 102100038356 Kallikrein-2 Human genes 0.000 description 1
- 102100025582 Leukocyte immunoglobulin-like receptor subfamily B member 3 Human genes 0.000 description 1
- 101150037847 MES1 gene Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 102100037273 Mammaglobin-A Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 1
- 108700041619 Myeloid Ecotropic Viral Integration Site 1 Proteins 0.000 description 1
- 102000047831 Myeloid Ecotropic Viral Integration Site 1 Human genes 0.000 description 1
- 102000004019 NADPH Oxidase 1 Human genes 0.000 description 1
- 108090000424 NADPH Oxidase 1 Proteins 0.000 description 1
- 102100032709 Potassium-transporting ATPase alpha chain 2 Human genes 0.000 description 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 1
- 102100027249 Protein EVI2B Human genes 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 108090000244 Rat Proteins Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 102100023916 Retinol dehydrogenase 11 Human genes 0.000 description 1
- 102100035914 S-adenosylmethionine decarboxylase proenzyme Human genes 0.000 description 1
- 101100097991 Schizosaccharomyces pombe (strain 972 / ATCC 24843) rar1 gene Proteins 0.000 description 1
- 102100036428 Spondin-1 Human genes 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100034738 Transcription factor LBX1 Human genes 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 108010069264 keratinocyte CD44 Proteins 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000002966 oligonucleotide array Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 101150112970 up gene Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/20—Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Evolutionary Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Complex Calculations (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36879002P | 2002-03-29 | 2002-03-29 | |
| US60/368790 | 2002-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1495272A true CN1495272A (zh) | 2004-05-12 |
Family
ID=27805329
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031312047A Pending CN1495272A (zh) | 2002-03-29 | 2003-03-29 | 选择标记物的方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20030194734A1 (enExample) |
| EP (1) | EP1349104A3 (enExample) |
| JP (1) | JP2004163388A (enExample) |
| KR (1) | KR20030078803A (enExample) |
| CN (1) | CN1495272A (enExample) |
| AR (1) | AR039212A1 (enExample) |
| AU (1) | AU2003203529A1 (enExample) |
| BR (1) | BR0303080A (enExample) |
| CA (1) | CA2422309A1 (enExample) |
| MX (1) | MXPA03002865A (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1361433A3 (en) * | 2002-04-09 | 2005-02-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Method for estimating therapeutic efficacy of tumor necrosis factor (TNF) |
| US20040191782A1 (en) * | 2003-03-31 | 2004-09-30 | Yixin Wang | Colorectal cancer prognostics |
| US20050186577A1 (en) | 2004-02-20 | 2005-08-25 | Yixin Wang | Breast cancer prognostics |
| US20090081645A1 (en) * | 2004-08-02 | 2009-03-26 | Hidehito Kotani | Method of assuming drug sensitivity to cdk4 inhibitor |
| CA2589782A1 (en) * | 2004-11-30 | 2006-06-08 | Veridex Llc | Lung cancer prognostics |
| KR100690250B1 (ko) * | 2005-01-31 | 2007-03-12 | 디지탈 지노믹스(주) | 폐암 진단용 마커 |
| WO2006080597A1 (en) * | 2005-01-31 | 2006-08-03 | Digital Genomics Inc. | Markers for the diagnosis of lung cancer |
| US20070037186A1 (en) | 2005-05-20 | 2007-02-15 | Yuqiu Jiang | Thyroid fine needle aspiration molecular assay |
| IL177006A0 (en) | 2005-08-02 | 2006-12-10 | Veridex Llc | Predicting bone relapse of breast cancer |
| US20070130694A1 (en) * | 2005-12-12 | 2007-06-14 | Michaels Emily W | Textile surface modification composition |
| US20070207467A1 (en) | 2006-03-01 | 2007-09-06 | Ming Xu | Detection of lymph node metastasis from gastric carcinoma |
| WO2008045133A2 (en) * | 2006-03-03 | 2008-04-17 | Veridex, Llc | Molecular assay to predict recurrence of dukes' b colon cancer |
| US8338109B2 (en) | 2006-11-02 | 2012-12-25 | Mayo Foundation For Medical Education And Research | Predicting cancer outcome |
| EP1939805A1 (en) * | 2006-12-22 | 2008-07-02 | X-Shares Advisors LLC | Portfolio selection for custom indices of public securities based on state of domicile of issuing company |
| US20080206777A1 (en) | 2007-02-27 | 2008-08-28 | Nuclea Biomarkers, Llc | Gene and protein expression profiles associated with the therapeutic efficacy of EGFR-TK inhibitors |
| BRPI0907440A2 (pt) * | 2008-01-22 | 2016-11-01 | Veridex Llc | estadiamento molecular de câncer de cólon em estágio ii e iii prognóstico |
| WO2009126543A1 (en) | 2008-04-08 | 2009-10-15 | Nuclea Biomarkers, Llc | Biomarker panel for prediction of recurrent colorectal cancer |
| EP2806054A1 (en) | 2008-05-28 | 2014-11-26 | Genomedx Biosciences Inc. | Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer |
| US10407731B2 (en) | 2008-05-30 | 2019-09-10 | Mayo Foundation For Medical Education And Research | Biomarker panels for predicting prostate cancer outcomes |
| CN107254538A (zh) | 2008-11-12 | 2017-10-17 | 卡里斯生命科学瑞士控股有限责任公司 | 使用外来体来确定表现型的方法和系统 |
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| US9495515B1 (en) | 2009-12-09 | 2016-11-15 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US9074258B2 (en) | 2009-03-04 | 2015-07-07 | Genomedx Biosciences Inc. | Compositions and methods for classifying thyroid nodule disease |
| WO2010124372A1 (en) | 2009-04-29 | 2010-11-04 | Genomedx Biosciences, Inc. | Systems and methods for expression-based classification of thyroid tissue |
| EP3360978A3 (en) | 2009-05-07 | 2018-09-26 | Veracyte, Inc. | Methods for diagnosis of thyroid conditions |
| US10446272B2 (en) | 2009-12-09 | 2019-10-15 | Veracyte, Inc. | Methods and compositions for classification of samples |
| KR20130056855A (ko) | 2010-03-01 | 2013-05-30 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 치료진단용 생물학적 지표들 |
| KR20130043104A (ko) | 2010-04-06 | 2013-04-29 | 카리스 라이프 사이언스 룩셈부르크 홀딩스 | 질병용 순환 생물학적 지표들 |
| US20130267443A1 (en) | 2010-11-19 | 2013-10-10 | The Regents Of The University Of Michigan | ncRNA AND USES THEREOF |
| WO2013090620A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
| ES2945036T3 (es) | 2012-08-16 | 2023-06-28 | Veracyte Sd Inc | Pronóstico del cáncer de próstata mediante biomarcadores |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| US20170335396A1 (en) | 2014-11-05 | 2017-11-23 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| AU2017315425B2 (en) | 2016-08-24 | 2023-11-09 | The Regents Of The University Of Michigan | Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy |
| EP3571322B9 (en) | 2017-01-20 | 2023-10-04 | VERACYTE SD, Inc. | Molecular subtyping, prognosis, and treatment of bladder cancer |
| CA3055925A1 (en) | 2017-03-09 | 2018-09-13 | Decipher Biosciences, Inc. | Subtyping prostate cancer to predict response to hormone therapy |
| US11078542B2 (en) | 2017-05-12 | 2021-08-03 | Decipher Biosciences, Inc. | Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness |
| US11217329B1 (en) | 2017-06-23 | 2022-01-04 | Veracyte, Inc. | Methods and systems for determining biological sample integrity |
| US12497660B2 (en) | 2017-08-04 | 2025-12-16 | Veracyte SD, Inc. | Use of immune cell-specific gene expression for prognosis of prostate cancer and prediction of responsiveness to radiation therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2005927A1 (en) * | 1988-12-21 | 1990-06-21 | Chander Bahl | Method of preparing nucleotide probes using a bridging complement |
| US6350576B1 (en) * | 1994-12-20 | 2002-02-26 | Cold Spring Harbor Laboratory | Cancer detection probes |
| US5972614A (en) * | 1995-12-06 | 1999-10-26 | Genaissance Pharmaceuticals | Genome anthologies for harvesting gene variants |
| US6275814B1 (en) * | 1996-11-27 | 2001-08-14 | Investment Strategies Network | Investment portfolio selection system and method |
| US6003018A (en) * | 1998-03-27 | 1999-12-14 | Michaud Partners Llp | Portfolio optimization by means of resampled efficient frontiers |
| US6882990B1 (en) * | 1999-05-01 | 2005-04-19 | Biowulf Technologies, Llc | Methods of identifying biological patterns using multiple data sets |
| US6401043B1 (en) * | 1999-04-26 | 2002-06-04 | Variagenics, Inc. | Variance scanning method for identifying gene sequence variances |
| US6175824B1 (en) * | 1999-07-14 | 2001-01-16 | Chi Research, Inc. | Method and apparatus for choosing a stock portfolio, based on patent indicators |
| KR20020092891A (ko) * | 1999-07-15 | 2002-12-12 | 리서치 디벨럽먼트 파운데이션 | 코르티코트로핀 분비 인자 수용체 2 결핍 마우스 및 이의용도 |
-
2003
- 2003-03-21 US US10/394,087 patent/US20030194734A1/en not_active Abandoned
- 2003-03-28 CA CA002422309A patent/CA2422309A1/en not_active Abandoned
- 2003-03-28 AU AU2003203529A patent/AU2003203529A1/en not_active Abandoned
- 2003-03-28 BR BR0303080-6A patent/BR0303080A/pt not_active IP Right Cessation
- 2003-03-29 KR KR10-2003-0019839A patent/KR20030078803A/ko not_active Withdrawn
- 2003-03-29 CN CNA031312047A patent/CN1495272A/zh active Pending
- 2003-03-31 EP EP03252027A patent/EP1349104A3/en not_active Withdrawn
- 2003-03-31 JP JP2003095679A patent/JP2004163388A/ja active Pending
- 2003-03-31 MX MXPA03002865A patent/MXPA03002865A/es unknown
- 2003-04-01 AR ARP030101133A patent/AR039212A1/es not_active Application Discontinuation
-
2009
- 2009-07-01 US US12/496,399 patent/US20100009371A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1349104A3 (en) | 2004-01-02 |
| JP2004163388A (ja) | 2004-06-10 |
| BR0303080A (pt) | 2004-02-17 |
| AR039212A1 (es) | 2005-02-09 |
| CA2422309A1 (en) | 2003-09-29 |
| AU2003203529A1 (en) | 2003-10-23 |
| KR20030078803A (ko) | 2003-10-08 |
| EP1349104A2 (en) | 2003-10-01 |
| US20030194734A1 (en) | 2003-10-16 |
| US20100009371A1 (en) | 2010-01-14 |
| MXPA03002865A (es) | 2004-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100577813C (zh) | 肿瘤诊断组合物 | |
| CN1495272A (zh) | 选择标记物的方法 | |
| AU2003203557B2 (en) | Breast cancer prognostic portfolio | |
| US7504214B2 (en) | Predicting outcome with tamoxifen in breast cancer | |
| US20040146907A1 (en) | Methods and compositions for detecting dysplasia | |
| US20060088823A1 (en) | Microarray gene expression profiling in clear cell renal cell carcinoma : prognosis and drug target identification | |
| CA2430981A1 (en) | Gene expression profiling of primary breast carcinomas using arrays of candidate genes | |
| CN1867679A (zh) | 用于胃癌检测的标记物 | |
| CN1839205A (zh) | 用于鉴定、评估、预防和治疗乳腺癌的组合物、试剂盒及方法 | |
| CN1500151A (zh) | Pcr方法 | |
| US20040241725A1 (en) | Lung cancer detection | |
| CN1542143A (zh) | 结直肠癌的预后 | |
| AU2006203169A1 (en) | Predicting bone relapse of breast cancer | |
| AU2008203227A1 (en) | Colorectal cancer prognostics | |
| KR20140040694A (ko) | 결장직장암 재발에 대한 예후 서명 | |
| CN101029342A (zh) | 对胃癌淋巴结转移的检测 | |
| CN1502989A (zh) | 测定结肠癌 | |
| CN1495273A (zh) | 评估结肠直肠癌 | |
| CN1637151A (zh) | 结肠直肠癌预后 | |
| CN1865440A (zh) | 肥厚型心肌病致病基因的新突变及其用途 | |
| CN1415760A (zh) | 转移相关基因 | |
| HK1141054A (en) | Tumor diagnostic composition | |
| CN1856573A (zh) | 用于神经母细胞瘤预后诊断的微阵列和神经母细胞瘤预后诊断方法 | |
| CN1890385A (zh) | 结肠直肠癌相关基因 | |
| CN101065393A (zh) | 用于结肠直肠癌早期检测的药物筛选和分子诊断检测：试剂、方法及其试剂盒 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |